🇺🇸 FDA
Patent

US 11497740

Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer

granted A61KA61K31/00A61K31/282

Quick answer

US patent 11497740 (Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer) held by The Board of Regents of the University of Texas System expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/00, A61K31/282, A61K31/337, A61K31/44